Oncotarget

Research Papers:

A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution

Jia-Jia Huang, Yi Xia, Yu Wang, Pan-Pan Liu, Xi-Wen Bi, Peng Sun, Tong-Yu Lin, Wen-Qi Jiang and Zhi-Ming Li _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:41242-41250. https://doi.org/10.18632/oncotarget.9271

Metrics: PDF 1448 views  |   HTML 1760 views  |   ?  


Abstract

Jia-Jia Huang1,2, Yi Xia1,2, Yu Wang1,2, Pan-Pan Liu1,2, Xi-Wen Bi1,2, Peng Sun1,2, Tong-Yu Lin1,2, Wen-Qi Jiang1,2, Zhi-Ming Li1,2

1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China

2Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China

Correspondence to:

Zhi-Ming Li, email: lzmsysu@hotmail.com

Keywords: R-EPOCH, DLBCL, Ki-67 expression, R-CHOP

Received: December 11, 2015     Accepted: March 31, 2016     Published: May 10, 2016

ABSTRACT

Diffuse large B-cell lymphoma (DLBCL) patients with high Ki-67 expression receive limited benefits from R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy. This study aims to compare the R-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) and R-CHOP regimens as first-line therapy in DLBCL patients with high Ki-67 expression. Data from 44 untreated DLBCL patients with high Ki-67 expression receiving R-EPOCH therapy were matched with those from 132 untreated DLBCL patients with high Ki-67 expression receiving R-CHOP therapy based on the International Prognostic Index (IPI: age, Ann Arbor stage, performance status, LDH level, number of extranodal sites), gender, and Ki-67 expression. In the R-EPOCH group, 42/44 patients were eligible for response evaluation. A total of 35 patients (83.3%) achieved complete remission (CR); 6 patients (14.3%) achieved partial remission (PR); and one patient (2.4%) exhibited progressive disease (PD) after 2 cycles of therapy. Patients in the R-EPOCH group presented better survival outcomes than those in the R-CHOP group (3-year overall survival [OS]: 89.9% vs. 70.2%, p = 0.041; 3-year progression-free survival [PFS]: 86.6% vs. 59.7%, p = 0.024). The survival superiority of the R-EPOCH over the R-CHOP regimen persisted when considering only patients of low-to-intermediate IPI risk, but it was not observed in those of high IPI risk. Our data suggest that R-EPOCH could be superior to R-CHOP as a first-line regimen in DLBCL patients with high Ki-67 expression, especially in those of low-to-intermediate IPI risk.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9271